# A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

Source: https://onco.cc/trials/nct06689163/  
OnCo record `nct06689163` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06689163 as recruiting, last updated 2025-09-03. Enrolment is 66 planned participants, an estimate. Interventions: HRS-1167 tablets, Abiraterone Acetate tablets（II）, Prednisone Acetate tablets. Primary measures include Dose limiting toxicity (DLT); Recommended phase II dose (RP2D). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Tags: ctgov-ingest
- Registry id: NCT06689163
- Phase: 1/2
- Setting: An Open, Multicenter Phase Ib/II Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.

## Sources

- ClinicalTrials.gov NCT06689163: https://clinicaltrials.gov/study/NCT06689163

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [HRS-1167](https://onco.cc/drugs/hrs-1167/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06689163.json